See Our Mission
We are dedicated to eliminating bacterial infections such as invasive pneumococcal disease, Group A Strep and periodontitis to protect every child born and every adult at risk across the globe.
Pushing the Boundaries of What’s Possible
Despite widespread vaccination with current pneumococcal conjugate vaccines (PCVs), there is an abundance of non-vaccine strains of the Streptococcus pneumoniae bacteria causing significant morbidity and mortality, underscoring the importance of advancing our lead program, VAX-24, a 24-valent PCV candidate. VAX-24 is currently the broadest-spectrum PCV in development and one of the most complex biologics ever created.
Re-Engineering How Vaccines are Made
We strive to overcome the limitations of conventional, cell-based vaccine approaches using advanced chemistry and modern synthetic techniques – including our XpressCF™ cell-free protein synthesis platform – to produce broad-spectrum vaccines that are uniquely capable of breaking down bacteria’s complex defense mechanisms while preserving immunogenicity.
Building a Pipeline of High-Fidelity and Broad-Spectrum Vaccines
Our PCV franchise is intended to improve upon existing pneumococcal vaccines by covering the serotypes responsible for most of the remaining pneumococcal disease currently in circulation. Following VAX-24, we are developing VAX-XP, a PCV candidate with an expanded breadth of coverage of greater than 30 strains of pneumococcal disease. Additional vaccine candidates in preclinical development target Group A Strep bacteria and periodontitis.
Vaxcyte Completes Enrollment of Phase 2 Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults 65 Years and Older
-- Company Expects to Announce Topline Data from Study in Adults 65 Years and Older in the First Half of 2023 -- -- Vaxcyte Remains on Track to Announce Topline Data from the Phase 1 and Phase 2 Portions of the VAX-24 Proof-of-Concept Study in Adults Aged 18-64 in October or November 2022 -- --
-- Completed Enrollment of Phase 2 Portion of Phase 1/2 Clinical Proof-of-Concept Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults -- -- Announcement of Topline Results from the Phase 1 and Phase 2 Portions of the VAX-24 Proof-of-Concept Study Expected in October or
-- Company Receives FDA Fast Track Designation for VAX-24 in Adults -- -- Vaxcyte Completes Successful Pre-IND Meeting with FDA Regarding VAX-24 Pediatric Program, Supporting Path to Proceed Directly into Infants -- -- VAX-24 is 24-Valent Pneumococcal Conjugate Vaccine Designed to Deliver
Careers: Built to Scale with Purpose
Looking for higher aspirations to ignite your mind and inspire your heart? Then join a team that brings grit and grace to the challenge of protecting every human from the consequences of endemic bacterial infections.